OCS - Oculis Holding AG

QQQ $ 454.82 $ 1.24 (0.27 %)

DIA $ 398.57 $ 1.27 (0.33 %)

SPY $ 530.36 $ 0.59 (0.11 %)

TLT $ 91.26 $ 1.07 (1.17 %)

GLD $ 225.37 $ -1.95 (-0.9 %)

Previous Close

$ 11.85

Open

$ 11.77

Bid

$ 11.75 x 100

Ask

$ 0.00 x 0

Day's Range

$ 11.77 - $ 11.80

52 Week Range

$ 9.05 - $ 14.50

Volume

11,667

Average Volume

Market Cap

194.32M

Beta (5Y Monthly)

$ 0.68

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Ocul...
05/30/2024 10:28:59

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $28 price target.

HC Wainwright & Co. Reiterates Buy on Ocul...
05/13/2024 11:15:22

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $28 price target.

Oculis Holding Q1 EPS $(0.50) Misses $(0.4...
05/08/2024 23:12:58

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.4...

Oculis Announces Completion Of Enrollment ...
05/08/2024 21:46:02

Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acut...

HC Wainwright & Co. Maintains Buy on Oculi...
04/24/2024 10:27:36

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $2...

Chardan Capital Maintains Buy on Oculis Ho...
03/19/2024 13:09:14

Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:OCS) with a Buy and maintains $30 price target.

Baird Maintains Outperform on Oculis Holdi...
03/19/2024 11:16:21

Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the price target from $64 to $35.

Oculis's 2023 Cash, Cash Equivalents, And ...
03/18/2024 10:39:23

Oculis Holding Q4 GAAP EPS CHF(0.34) Up Fr...
03/18/2024 10:37:33

Wedbush Reiterates Outperform on Oculis Ho...
03/06/2024 16:09:24

Wedbush analyst Andreas Argyrides reiterates Oculis Holding (NASDAQ:OCS) with a Outperform and maintains $29 price target.

HC Wainwright & Co. Reiterates Buy on Ocul...
02/29/2024 14:04:21

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $29 price target.

Oculis Updates On Late-Stage Clinical Tria...
02/28/2024 11:35:35

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry...

flj-group-bit-digital-and-other-big-stocks-moving-higher-in-fridays-pre-market-session

FLJ Group, Bit Digital And Other Big Stock...
12/29/2023 10:39:58

U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 15 points on Thursday. Shares ...

Oculis Announces First Patient First Visit...
12/20/2023 11:38:38

Initiation of the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop, follows the recently reported positive OPTIM...

Oculis Announces First Patient First Visit...
12/18/2023 11:37:24

Oculis Announces First Patient First Visit...
12/07/2023 11:36:14

Chardan Capital Initiates Coverage On Ocul...
12/05/2023 13:45:42

Chardan Capital analyst Daniil Gataulin initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rating and announces Pr...

Expert Ratings for Oculis Holding
11/17/2023 15:00:45

Wedbush Reiterates Outperform on Oculis Ho...
11/17/2023 14:14:12

Wedbush analyst Andreas Argyrides reiterates Oculis Holding (NASDAQ:OCS) with a Outperform and maintains $29 price target.

Benzinga's Top Ratings Upgrades, Downgrade...
10/05/2023 15:00:45